Our strategy is to develop our portfolio of innovative products for sexual health and and then partner at the optimum time to generate most shareholder value.
The objective is to develop products such that each on its own has the potential to generate significant long-term annual revenues.
We are investing in our lead product Eroxon to generate most value for shareholders.